SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167783680> ?p ?o ?g. }

Showing items 1 to 85 of 85 with 100 items per page.

W2167783680 abstract "When the National Cancer Act was signed into law in 1971, mastectomy was the only accepted surgical option for breast cancer treatment, and there were a limited number of systemic therapies, none formally approved as adjuvant therapy. Tamoxifen was still 6 years away from approval as a breast cancer therapy in the United States. One randomized trial of screening mammography was underway, and none had reported results. BRCA mutations and their relationship with breast cancer risk would not be discovered for another two decades. The annual age-adjusted breast cancer mortality rate was about 31 per 100,000, and at least 25% of all patients with breast cancer died as a result of their disease within 5 years of diagnosis. The past 40 years have seen remarkable advances in breast cancer treatment, early detection, and outcomes. Breast conservation was established as equivalent to mastectomy. Adjuvant therapy was shown to reduce risks of recurrence and death leading to global adoption of evidence-based postoperative systemic treatments. Early detection has been accepted as a key component of breast cancer care, and now more than two thirds of women age 40 years or older receive screening mammography. With gene sequencing technologies, we can identify BRCA mutation carriers and offer them more intensive screening and options to reduce their breast cancer risk. Now, despite an aging and more obese population, annual age-adjusted breast cancer mortality is about 21 per 100,000, and 5-year relative survival exceeds 90%. Clearly we have made progress, but planning for additional gains means, in part, determining where we have done well and which interventions, if any, might be less useful than we thought. In the accompanying article, Park et al examine trends in breast cancer characteristics and outcomes from 1973 through 2010, attempting to explain the proportions of observed improvement in breast cancer mortality and survival that are associated with changes in the distribution of tumor characteristics, specifically size and estrogen receptor (ER) status. Their motivating logic is that changes in tumor characteristics likely reflect interventions such as screening that occur before diagnosis. The proportion of improvement that remains unexplained by trends in tumor characteristics must be explained by interventions that happen after diagnosis, chiefly treatment. Using population-based data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry program, Park et al compare breast cancer–specific mortality and survival in cohorts diagnosed from 2005 to 2010 with those diagnosed from 1973 to 1979, stratified by stage and age at diagnosis. They find that, in the first 5 years after diagnosis in women age 50 to 69 years with localized disease, change in the distribution of tumor size explained less than 20% of the observed improvement in breast cancer–specific mortality. It also explained less than 10% of the mortality improvement in those with regional or distant disease. Among women age 70 years or older, changes in tumor size explained a much larger proportion of the observed improvement in cancer-specific mortality: 49%, 38%, and 20%, respectively, in those with local, regional, and distant disease. Changes in the distribution of ER status did not seem to explain a substantial fraction of improvement in breast cancer outcomes, beyond the proportion explained by changes in tumor size. Comparing cohorts diagnosed from 2005 to 2010 with those diagnosed from 1990 to 1995 (when information on ER status was first available in SEER), changes in ER status seemed to have the greatest explanatory power among women with metastatic disease in all age groups, both less than 5 years after diagnosis and 5 or more years after diagnosis. Although the incidence of ER-positive breast cancer has increased over time, particularly among screen-detected cancers, its greater role in explaining mortality trends for advanced disease rather than localized disease suggests that the impact of ER status on population outcomes may reflect the expansion and dissemination of hormonal therapy options more than the uptake of screening. Overall, the findings from Park et al suggest that aspects of breast cancer treatment underlie much of the observed improvement in breast cancer mortality and survival between the 1970s and 2000s. Those decades saw remarkable scientific advances, including identification of the human epidermal growth factor receptor 2-neu (HER2neu) oncogene and development of the targeted agent trastuzumab, which extends survival in both the adjuvant and metastatic settings for the 15% to 25% of patients with HER2-positive tumors. Information regarding HER2 status was not routinely collected in SEER before 2010, and therefore its contribution to improvements in breast cancer mortality and survival could not be studied here. However, this advance, in addition to the switch from tamoxifen to aromatase inhibitors for postmenopausal women and the use of taxanes and dose-dense chemotherapy regimens for higher-risk early-stage presentations, should mean that the total impact of therapy has indeed increased. During that time, consensus conferences and expert guidelines promoted the more consistent use of these treatments, likely increasing the proportion of women appropriately receiving beneficial systemic therapy. Prior studies have drawn similar conclusions but found a greater contribution of screening to observed changes in outcomes. Using methods similar to those of Park et al but comparing women diagnosed from 1995 to 1999 with women diagnosed from 1975 to 1979, we found that changes in the tumor size distribution explained 61% of JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 33 NUMBER 26 SEPTEMBER 1" @default.
W2167783680 created "2016-06-24" @default.
W2167783680 creator A5047713528 @default.
W2167783680 creator A5063707394 @default.
W2167783680 date "2015-09-10" @default.
W2167783680 modified "2023-09-24" @default.
W2167783680 title "Parsing Progress in Breast Cancer" @default.
W2167783680 cites W1490802304 @default.
W2167783680 cites W1989421209 @default.
W2167783680 cites W2045216597 @default.
W2167783680 cites W2058235978 @default.
W2167783680 cites W2075184801 @default.
W2167783680 cites W2109997465 @default.
W2167783680 cites W2110560439 @default.
W2167783680 cites W2138977450 @default.
W2167783680 cites W2143305439 @default.
W2167783680 cites W2162960834 @default.
W2167783680 doi "https://doi.org/10.1200/jco.2015.62.4890" @default.
W2167783680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26261261" @default.
W2167783680 hasPublicationYear "2015" @default.
W2167783680 type Work @default.
W2167783680 sameAs 2167783680 @default.
W2167783680 citedByCount "10" @default.
W2167783680 countsByYear W21677836802014 @default.
W2167783680 countsByYear W21677836802015 @default.
W2167783680 countsByYear W21677836802016 @default.
W2167783680 countsByYear W21677836802018 @default.
W2167783680 countsByYear W21677836802020 @default.
W2167783680 crossrefType "journal-article" @default.
W2167783680 hasAuthorship W2167783680A5047713528 @default.
W2167783680 hasAuthorship W2167783680A5063707394 @default.
W2167783680 hasConcept C121608353 @default.
W2167783680 hasConcept C126322002 @default.
W2167783680 hasConcept C143998085 @default.
W2167783680 hasConcept C2777176818 @default.
W2167783680 hasConcept C2777757722 @default.
W2167783680 hasConcept C2777982462 @default.
W2167783680 hasConcept C2779134260 @default.
W2167783680 hasConcept C2780472235 @default.
W2167783680 hasConcept C2908647359 @default.
W2167783680 hasConcept C29456083 @default.
W2167783680 hasConcept C530470458 @default.
W2167783680 hasConcept C71924100 @default.
W2167783680 hasConcept C99454951 @default.
W2167783680 hasConceptScore W2167783680C121608353 @default.
W2167783680 hasConceptScore W2167783680C126322002 @default.
W2167783680 hasConceptScore W2167783680C143998085 @default.
W2167783680 hasConceptScore W2167783680C2777176818 @default.
W2167783680 hasConceptScore W2167783680C2777757722 @default.
W2167783680 hasConceptScore W2167783680C2777982462 @default.
W2167783680 hasConceptScore W2167783680C2779134260 @default.
W2167783680 hasConceptScore W2167783680C2780472235 @default.
W2167783680 hasConceptScore W2167783680C2908647359 @default.
W2167783680 hasConceptScore W2167783680C29456083 @default.
W2167783680 hasConceptScore W2167783680C530470458 @default.
W2167783680 hasConceptScore W2167783680C71924100 @default.
W2167783680 hasConceptScore W2167783680C99454951 @default.
W2167783680 hasLocation W21677836801 @default.
W2167783680 hasLocation W21677836802 @default.
W2167783680 hasOpenAccess W2167783680 @default.
W2167783680 hasPrimaryLocation W21677836801 @default.
W2167783680 hasRelatedWork W111220734 @default.
W2167783680 hasRelatedWork W122560183 @default.
W2167783680 hasRelatedWork W172766237 @default.
W2167783680 hasRelatedWork W1930410940 @default.
W2167783680 hasRelatedWork W1966592273 @default.
W2167783680 hasRelatedWork W1973231919 @default.
W2167783680 hasRelatedWork W2029167978 @default.
W2167783680 hasRelatedWork W2036448565 @default.
W2167783680 hasRelatedWork W2038276007 @default.
W2167783680 hasRelatedWork W2091505987 @default.
W2167783680 hasRelatedWork W2143305439 @default.
W2167783680 hasRelatedWork W2295607659 @default.
W2167783680 hasRelatedWork W2560410528 @default.
W2167783680 hasRelatedWork W2589044944 @default.
W2167783680 hasRelatedWork W2599447563 @default.
W2167783680 hasRelatedWork W2948456083 @default.
W2167783680 hasRelatedWork W3010986624 @default.
W2167783680 hasRelatedWork W3013011333 @default.
W2167783680 hasRelatedWork W3044152155 @default.
W2167783680 hasRelatedWork W3160410205 @default.
W2167783680 isParatext "false" @default.
W2167783680 isRetracted "false" @default.
W2167783680 magId "2167783680" @default.
W2167783680 workType "article" @default.